InspireMD Inc ( (NSPR) ) has released its Q3 earnings. Here is a breakdown of the information InspireMD Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InspireMD, Inc. is a medical device company specializing in the development of the CGuard® Prime carotid stent system, aimed at preventing strokes and transforming the carotid intervention market with its proprietary MicroNet™ mesh technology.
In its third-quarter 2025 earnings report, InspireMD announced a successful initial U.S. commercial launch of its CGuard Prime carotid stent system, contributing to record quarterly revenue. The company also highlighted strategic leadership appointments to strengthen its operational capabilities.
The financial results for the third quarter of 2025 showed a 39% increase in total revenue, reaching $2.5 million compared to $1.8 million in the same period last year. This growth was driven by the U.S. launch of CGuard Prime and increased international market penetration. Despite the revenue growth, the company reported a net loss of $12.7 million, up from $7.9 million in the previous year, primarily due to increased operating expenses related to expanding its U.S. commercial team and establishing a U.S. headquarters.
InspireMD’s management remains optimistic about the company’s future, emphasizing the strong global demand for its solutions and the potential for continued growth. With a strengthened balance sheet and strategic focus on expanding its market presence, InspireMD aims to deliver long-term value and advance its mission in the carotid intervention market.